Meihua International Medical Technologies (NASDAQ:MHUA) & Profound Medical (NASDAQ:PROF) Head-To-Head Contrast

Profound Medical (NASDAQ:PROF) and Meihua International Medical Technologies (NASDAQ:MHUA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for Profound Medical and Meihua International Medical Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profound Medical	0	0	2	0	3.00
Meihua International Medical Technologies	0	0	0	0	0.00

Profound Medical presently has a consensus price target of $11.50, suggesting a potential upside of 144.16%. Given Profound Medical’s stronger consensus rating and higher probable upside, equities analysts clearly believe Profound Medical is more favorable than Meihua International Medical Technologies.

Volatility and Risk

Profound Medical has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500. Comparatively, Meihua International Medical Technologies has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500.

Earnings and Valuation

This table compares Profound Medical and Meihua International Medical Technologies”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profound Medical	$11.86 million	11.93	-$28.57 million	($1.22)	-3.86
Meihua International Medical Technologies	$96.91 million	0.10	$11.62 million	N/A	N/A

Meihua International Medical Technologies has higher revenue and earnings than Profound Medical.

Institutional and Insider Ownership

47.9% of Profound Medical shares are owned by institutional investors. Comparatively, 1.2% of Meihua International Medical Technologies shares are owned by institutional investors. 1.5% of Profound Medical shares are owned by company insiders. Comparatively, 66.6% of Meihua International Medical Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Profound Medical and Meihua International Medical Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Profound Medical	-349.41%	-85.22%	-64.87%
Meihua International Medical Technologies	N/A	N/A	N/A

Summary

Meihua International Medical Technologies beats Profound Medical on 7 of the 12 factors compared between the two stocks.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.

About Meihua International Medical Technologies

Meihua International Medical Technologies Co., Ltd. engages in the manufacture, sells, and marketing of medical consumables in the People's Republic of China. The company offers class I, II, and III disposable medical devices. Its products include non-bottled products, such as brushes and ID bracelets; and polyethylene bottled products, such as eye drop and tablet bottles, as well as electronic pumps. The company also distributes disposable medical devices sourced from other manufacturers to customers in China. In addition, it offers COVID-19 products comprising disposable medical masks. The company serves hospitals, pharmacies, medical institutions, and medical equipment companies. It also exports its products to Europe, North America, South America, Asia, Africa, and Oceania. The company was founded in 1991 and is based in Yangzhou, the People's Republic of China. Meihua International Medical Technologies Co., Ltd. operates as a subsidiary of Bright Accomplish Limited.